WO2023245021A3 - Multispecific binding agents that target cd25 and/or ctla4 and uses thereof - Google Patents

Multispecific binding agents that target cd25 and/or ctla4 and uses thereof Download PDF

Info

Publication number
WO2023245021A3
WO2023245021A3 PCT/US2023/068383 US2023068383W WO2023245021A3 WO 2023245021 A3 WO2023245021 A3 WO 2023245021A3 US 2023068383 W US2023068383 W US 2023068383W WO 2023245021 A3 WO2023245021 A3 WO 2023245021A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding agents
ctla4
target
multispecific binding
binding
Prior art date
Application number
PCT/US2023/068383
Other languages
French (fr)
Other versions
WO2023245021A2 (en
Inventor
Bonnie HAMMER
Dileep Kumar PULUKKUNAT
Original Assignee
Invenra Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invenra Inc. filed Critical Invenra Inc.
Publication of WO2023245021A2 publication Critical patent/WO2023245021A2/en
Publication of WO2023245021A3 publication Critical patent/WO2023245021A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present disclosure provides binding agents (e.g., antibodies, including multispecific binding agents, such as bispecific antibodies) that have a first binding domain that binds to CD25, including human CD25, and one or more additional binding domains that bind to one or more targets that are not CD25, such as CTLA4, and uses thereof.
PCT/US2023/068383 2022-06-14 2023-06-13 Multispecific binding agents that target cd25 and/or ctla4 and uses thereof WO2023245021A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263352210P 2022-06-14 2022-06-14
US63/352,210 2022-06-14
US202263375907P 2022-09-16 2022-09-16
US63/375,907 2022-09-16

Publications (2)

Publication Number Publication Date
WO2023245021A2 WO2023245021A2 (en) 2023-12-21
WO2023245021A3 true WO2023245021A3 (en) 2024-01-18

Family

ID=89191925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/068383 WO2023245021A2 (en) 2022-06-14 2023-06-13 Multispecific binding agents that target cd25 and/or ctla4 and uses thereof

Country Status (1)

Country Link
WO (1) WO2023245021A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260716A1 (en) * 2004-03-08 2005-11-24 Moore Margaret D Dimeric fusion proteins and materials and methods for producing them
US20180118811A1 (en) * 2016-10-19 2018-05-03 Invenra Inc. Antibody constructs
US20190127472A1 (en) * 2017-10-27 2019-05-02 New York University Anti-galectin-9 antibodies and uses thereof
US20190135925A1 (en) * 2016-04-07 2019-05-09 Cancer Research Technology Limited Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
US20220153844A1 (en) * 2020-01-13 2022-05-19 Invenra Inc. Multispecific treg binding molecules
WO2022125986A1 (en) * 2020-12-10 2022-06-16 Invenra Inc. Orthogonal mutations for heterodimerization

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260716A1 (en) * 2004-03-08 2005-11-24 Moore Margaret D Dimeric fusion proteins and materials and methods for producing them
US20190135925A1 (en) * 2016-04-07 2019-05-09 Cancer Research Technology Limited Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
US20180118811A1 (en) * 2016-10-19 2018-05-03 Invenra Inc. Antibody constructs
US20190127472A1 (en) * 2017-10-27 2019-05-02 New York University Anti-galectin-9 antibodies and uses thereof
US20220153844A1 (en) * 2020-01-13 2022-05-19 Invenra Inc. Multispecific treg binding molecules
WO2022125986A1 (en) * 2020-12-10 2022-06-16 Invenra Inc. Orthogonal mutations for heterodimerization

Also Published As

Publication number Publication date
WO2023245021A2 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
WO2018237148A8 (en) Multispecific antibodies that target hiv gp120 and cd3
WO2015184349A3 (en) Multivalent ras binding compounds
MX2009004532A (en) Compositions and methods for binding sphingosine-1-phosphate.
EA201992526A1 (en) STABILITIES OF ANTI-CTLA4 ANTIBODIES, SEPARATELY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF APPLICATION
WO2019160751A3 (en) Methods for treating cancer with anti-pd-1 antibodies
MX2022006578A (en) Antibodies specific for cd47, pd-l1, and uses thereof.
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
WO2020139926A3 (en) Anti-ctla4 antibodies and methods of use thereof
MX2021005048A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof.
WO2022031940A3 (en) Il28ra binding molecules and methods of use
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
WO2022031710A3 (en) Multispecific binding agents and uses thereof
AU2018278730A1 (en) A novel anti-c-Met antibody and use thereof
MX2022002239A (en) Igm glycovariants.
WO2022031884A3 (en) Il2rg binding molecules and methods of use
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
WO2021022304A3 (en) Bispecific anti lrrc15 and cd3epsilon antibodies
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein
MX2021010116A (en) Anti-pd-l1 antibody and use thereof.
MX2023004275A (en) Anti-pd-1/cd40 bispecific antibodies and uses thereof.
MX2021009275A (en) Cd3-specific binding molecules.
MX2022016322A (en) High affinity antibodies targeting tau phosphorylated at serine 413.
WO2023245021A3 (en) Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
MX2022000379A (en) Antibodies which bind to cancer cells and target radionuclides to said cells.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23824765

Country of ref document: EP

Kind code of ref document: A2